Contact Us
Drug Search Results
More Filters [+]

LY2090314

Alternative Names: ly2090314
Latest Update: 2024-05-01
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: GSK3 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Eli Lilly
Company Location: INDIANAPOLIS IN 46285
Company CEO: David A. Ricks
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for LY2090314

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Pancreatic Cancer|Leukemia

Phase 1: Oncology Solid Tumor Unspecified

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success
I2H-MC-JWYD

P2

Terminated

Pancreatic Cancer

2015-06-01

I2H-MC-JWYB

P2

Completed

Leukemia

2012-12-01

I2H-MC-JWYA

P1

Completed

Oncology Solid Tumor Unspecified

2011-04-01

Recent News Events

Date

Type

Title

05/01/2024

PubMed

 Interleukin 21 Drives a Hypermetabolic State and CD4+ T-Cell-Associated Pathogenicity in Chronic Intestinal Inflammation.

03/30/2024

PubMed

 Synthetic Lethality between Cohesin and WNT Signaling Pathways in Diverse Cancer Contexts.

03/01/2024

PubMed

 Ambient particulate matter exposure induces ferroptosis in hippocampal cells through the GSK3B/Nrf2/GPX4 pathway.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you’ve used PRYZM, we hope you’re able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions